Background {#Sec1}
==========

Soft tissue sarcomas (STSs) are rare and aggressive neoplasms of mesenchymal origin that account for approximately 1--2% of all adults cancers \[[@CR1], [@CR2]\]. Despite the improvement in surgical procedures and the development of adjuvant therapy \[[@CR3]\], the long-term survival of STS patients with high-grade tumors is still poor. More than 50% of patients with high-risk STS will develop metastases and death \[[@CR4]--[@CR6]\]. Hence, it is necessary to develop effective biomarkers to identify STS patients at high risk of tumor recurrence and death after surgical treatment.

A hypercoagulable state is correlated with malignancy and it has been showed in almost 50% of the patients with tumor \[[@CR7]\]. Among coagulation factors, fibrinogen have been in the limelight due to an essential role in inflammation as well as the development and progression of cancer. Many articles revealed that elevated preoperative plasma fibrinogen levels are significantly correlative with treatment failure or poor outcome in various malignancies \[[@CR8]--[@CR10]\], including STS \[[@CR11], [@CR12]\]. Additionally, accumulating data have demonstrated that preoperative malnutrition is associated with significantly short survival in STS patients \[[@CR13]\], with serum albumin serving as a crucial parameter for nutritional status.

Therefore, we propose a novel marker, namely, the preoperative fibrinogen/albumin ratio (FAR) in combination with coagulation and nutritional status to investigate its prognostic impact in patients with operable STS. We also assessed any links between the FAR and clinicalpathological characteristics.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

A total of 310 STS patients who underwent radical or palliative resection in Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China from October 1999 to August 2013 were enrolled in this study. The inclusion criteria were (1) pathological diagnosis of STS; (2) surviving at least 30 days postoperatively; and (3) without neoadjuvant therapy before serum collection.

Clinical data collection {#Sec4}
------------------------

Laboratory data, including counts of neutrophils, platelets and lymphocytes as well as fibrinogen and albumin (Alb) levels, were collected from blood samples that had been obtained before breakfast within 1 week prior to surgery. Clinical information were obtained retrospectively from the medical record. The stage of each patient was classified according to the American Joint Committee on Cancer (AJCC) 7th Edition \[[@CR14]\] and tumors were graded according to the French Federation of Cancer Centers Sarcoma Group (FNCLCC) grading system \[[@CR15]\]. Tumor margins were defined as follows: R0, negative/clean margins; R1, positive/involved margins (microscopic); R2, positive/involved margins (macroscopic), and Rx, the presence of residual tumor cannot be assessed). The NLR was defined by dividing the neutrophil count by the lymphocyte count. The PLR was defined by dividing the platelet count by the lymphocyte count. The FAR was defined by dividing the fibrinogen level by the Alb level.

The authenticity of this article was validated by uploading the key raw data to the Research Data Deposit public platform ([www.researchdata.org.cn](http://www.researchdata.org.cn)) with the approval RDD number of RDDA2017000360.

Patient follow-up {#Sec5}
-----------------

The independent follow-up program department in Sun Yat-sen University provided follow-up appointments at regular intervals. The follow-up time was calculated from the date of diagnosis to the latest follow-up date (May 01, 2017) or death. The Overall survival (OS) was defined as the time interval between the initial surgery and death from any cause or the last follow-up, while the disease free survival (DFS) was defined as the time from the initial surgery until recurrence or metastasis.

Statistical analysis {#Sec6}
--------------------

The data are expressed as the number (%), and the differences between groups were analyzed by chi-square (χ2) test or Fisher's exact test. The optimal cutoff point was determined by the maximum Youden index (YI) based on receiver operating characteristic (ROC) analysis, and areas under the curve (AUCs) were calculated. Survival curves were analyzed according to the Kaplan-Meier method and compared by the log-rank test. Univariate and multivariate analyses of survival were conducted using the Cox proportional hazards model with forward stepwise method. Hazard ratios (HR) estimated from the Cox analysis were reported as relative risks with corresponding 95% confidence intervals (CIs). A two-sided *P*\<0.05 was considered significant. All statistical operations were performed using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA.).

Results {#Sec7}
=======

Patient and tumor characteristics {#Sec8}
---------------------------------

The demographic variables and clinicopathological characteristics of 310 STS patients enrolled in the study are listed in Table [1](#Tab1){ref-type="table"}. There were 174 men and 136 women at a ratio of 1.3:1, with a median age of 39 years (range: 5--78 years). At the last follow-up, 98 (31.6%) had died, and 112 (36.1%) had relapsed.Table 1Baseline characteristics of all patientsCharacteristicsCasesPercentage (%)Sex310 Male17456.1 Female13643.9Age at operation (years) \< 5020867.1 ≥ 5010232.9Performance status 023776.5 ≥ 17323.5Body mass index (kg/m^2^) \< 18.54213.5 ≥ 18.5 to\< 25.020867.1 ≥ 25.06019.4Pathological types Fibrosarcoma5919.0 liposarcoma3711.9 Undifferentiated pleomorphic sarcoma/MFH7825.2 Leiomyosarcoma175.5 Synovial sarcoma4012.9 Rhabdomyosarcoma196.1 Alveolar soft part sarcoma92.9 Angiosarcoma82.6 Malignant peripheral nerve sheath tumor154.8 Mesenchymal chondrosarcoma82.6 Others206.5Tumor size (cm) \< 514346.1 ≥ 516753.9Tumor site Upper extremity3511.3 Lower extremity8226.5 Thoracic/trunk/abdominal wall9129.4 Intra-abdominal4815.5 Head/neck4815.5 Others61.9Tumor depth Superficial12741.0 Deep18359.0Tumor grade G18226.5 G211938.4 G38025.8 Missing299.4Surgical margin R027995.2 R193.1 R231.0 Rx20.7AJCC stage IA + IB8326.8 IIA + IIB14145.5 III + IV6220.0 Missing247.1NLR \< 2.5121469.0 ≥ 2.519631.0PLR \< 191.126585.5 ≥ 191.14514.5FAR \< 0.072617656.8 ≥ 0.072612443.2End-point Alive21268.4 Dead9831.6Recurrence YES11236.1 NO19863.9Metastasis YES6119.7 NO24980.3Adjuvant therapy None25782.9 Chemotherapy144.5 Radiotherapy165.2 Combined chemoradiotherapy20.6 Unknown216.8

Our results demonstrated that the median fibrinogen and Alb value in the preoperative blood sample was 2.870 g/L (range: 0.18--9.87 g/L), and 42.80 g/L (range: 26.20--57.70 g/L) respectively. Regarding the different pathological tumor subtypes, there were 78 patients (25.2%) with malignant fibrous histiocytoma (MFH), 59 (19.0%) with fibrosarcoma, 40 (12.9%) with synovial sarcoma, and 37 (11.9%) with liposarcoma. Surgical resection was performed in 293 patients, R0 were detected in 279 cases (95.2%), 9 (3.1%) cases were classified R1, and only 3 cases as R2 (1.0%). The grade classification was determined to be G1 in 82 patients (26.5%), G2 in 119 patients (38.4%), and G3 in 80 patients (25.8%). Most patients had stage II disease (141, 45.5%); 83 (26.8%) had stage I disease, and 62 (20.0%) had stage III or IV disease.

The individualized radiotherapy and chemotherapy protocols were designed after operation based on the histological types, tumor stage and patient's desire.

Determination of the optimal cut-off value {#Sec9}
------------------------------------------

After calculating the maximum of Youden index (sensitivity+specificity-1) and the AUC (Fig. [1](#Fig1){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Table S1), the optimal cutoff values of the FAR, PLR and NLR were set at 0.0726 (AUC: 0.680), 191.1 (AUC: 0.614) and 2.51 (AUC: 0.608).Fig. 1ROC curve analyses for prognostic indicators

Correlation between FAR and Clinicopathological characteristics {#Sec10}
---------------------------------------------------------------

A total of 134 patients (43.2%) were categorized as high FAR (≥0.0726), and 176 patients (56.8%) were categorized as low FAR group (\< 0.0726) according to the optimal cutoff value. An elevated FAR was significantly associated with age (*P* \< 0.001), tumor diameter (*P* \< 0.001), tumor depth (*P* \< 0.001), tumor grade (*P* = 0.002), AJCC stage (*P* = 0.001) and other inflammatory markers (NLR, PLR), but not with gender (*P* = 0.779). The associations between the FAR and other variables are presented in Table [2](#Tab2){ref-type="table"}.Table 2Correlation between the FAR and clinicopathological variables in STS patientsVariablesFAR*p*-value\< 0.0726, n (%)≥0.0726, n (%)Gender Male100 (56.8)74 (55.2)0.779 Female76 (43.2)60 (44.8)Age (years) \< 50136 (77.3)72 (53.7)\<0.001 ≥ 5040 (22.7)62 (46.3)Tumor size (cm)\<0.001 \< 598 (55.7)45 (33.6) ≥ 578 (44.3)89 (66.4)Tumor depth\<0.001 Superficial92 (52.3)35 (26.1) Deep84 (47.7)99 (73.9)Tumor grade0.002 G160 (34.1)22 (16.4) G264 (36.4)55 (41.0) G335 (19.9)45 (3.6) Missing17 (9.7)12 (9.0)AJCC stage0.001 IA + IB61 (34.7)22 (16.4) IIA + IIB75 (42.6)66 (49.3) III + IV25 (14.2)37 (27.6) Unknown15 (8.5)9 (6.7)NLR \< 2.51148 (84.1)66 (49.3)\<0.001 ≥ 2.5128 (15.9)68 (50.7)PLR\<0.001 \< 191.1165 (93.8)100 (74.6) ≥ 191.111 (6.3)34 (25.4)Recurrence0.001 YES50 (28.4)62 (46.3) NO126 (71.6)72 (53.7)Metastasis0.005 YES25 (14.2)36 (26.9) NO151 (85.8)98 (73.1)

Survival analysis {#Sec11}
-----------------

At a median follow-up period of 91.5 months, the incidence of local recurrence in the low FAR group (62 of 134, 46.3%) was significantly higher than that in the high FAR group (50 of 176, 28.4%) (*P* = 0.001).

Regarding OS, the high-FAR group exhibited a shorter median OS and lower 5-year OS rate than the low-FAR group (61.0 vs 115.8 months, *P* \< 0.001; 56.7% vs 82.4%, *P* \< 0.001), respectively (Fig. [2a](#Fig2){ref-type="fig"}). Multivariate analysis revealed that preoperative FAR was an independent prognostic factor for OS (HR: 1.907; 95% CI: 1.161--3.132; *P* = 0.011). Tumor depth, tumor grade and PLR were also identified as independent predictors, whereas the tumor size, AJCC stage and NLR were not (Table [3](#Tab3){ref-type="table"}).Fig. 2Kaplan-Meier curves showing OS (**a**) and DFS (**b**) according to the optimal value of FAR in STS patientsTable 3Univariate and multivariate analyses of variables for overall survival in STS patientsVariablesOS Univariate analysisOS Multivariate analysisHR (95% CI)*p*-valueHR (95% CI)*p*-valueSex Male1 (referent) Female1.304 (0.877--1.937)0.190Age (years) \< 501 (referent) ≥ 501.195 (0.793--1.02)0.395Tumor size (cm) \< 51 (referent) ≥ 51.676 (1.109--2.535)0.014Tumor depth Superficial1 (referent)1 (referent) Deep3.174 (1.942--5.190)\<0.0011.905 (1.098--3.305)0.022Tumor grade G11 (referent)1 (referent) G24.339 (1.821--10.336)0.0013.090 (1.283--7.440)0.012 G310.918 (4.647--25.652)\<0.0016.527 (2.715--15.693)\<0.001AJCC stage IA + IB1 (referent) IIA + IIB4.571 (2.065--10.115)\<0.001 III + IV9.540 (4.224--21.544)\<0.001NLR \< 2.511 (referent) ≥ 2.512.229 (1.497--3.318)\<0.001PLR \< 191.11 (referent)1 (referent) ≥ 191.13.585 (2.327--5.522)\<0.0011.936 (1.175--3.188)0.009FAR \< 0.07261 (referent)1 (referent) ≥ 0.07263.147 (2.068--4.787)\<0.0011.907 (1.161--3.132)0.011

Patients in the low-FAR group demonstrated a median DFS of 76 months while a median DFS of 21 months was observed for those in the high-FAR group (Fig. [2b](#Fig2){ref-type="fig"}).

In univariate analysis, a high FAR was significantly associated with a shorter DFS (HR: 1.956; 95% CI:1.408--2.718; *P* \< 0.001). However, on multivariate analysis, FAR was no longer an independent predictor of DFS, but the age, tumor depth, grade and NLR were statistically significant independent predictors of DFS (Table [4](#Tab4){ref-type="table"}).Table 4Univariate and multivariate analyses of variables for disease-free survival in STS patientsVariablesDFS Univariate analysisDFS Multivariate analysisHR (95% CI)*p*-valueHR (95% CI)*p*-valueSex Male1 (referent) Female1.014 (0.730--1.409)0.934Age (years) \< 501 (referent)1 (referent) ≥ 501.538 (1.103--2.145)0.0111.601 (1.111--2.306)0.012Tumor size (cm) \< 51 (referent) ≥ 52.181 (1.537--3.093)\<0.001Tumor depth Superficial1 (referent)1 (referent) Deep3.006 (2.043--4.422)\<0.0012.346 (1.541--3.571)\<0.001Tumor grade G11 (referent)1 (referent) G22.268 (1.340--3.837)0.0021.798 (1.053--3.069)0.031 G35.300 (3.132--8.71)\<0.0014.404 (2.565--7.561)\<0.001AJCC stage IA + IB1 (referent) IIA + IIB2.294 (1.402--3.751)0.001 III + IV5.089 (3.014--8.590)\<0.001NLR \< 2.511 (referent)1 (referent) ≥ 2.511.778 (1.271--2.487)0.0011.719 (1.195--2.471)0.003PLR \< 191.11 (referent) ≥ 191.12.498 (1.688--3.698)\<0.001FAR \< 0.07261 (referent) ≥ 0.07261.956 (1.408--2.718)\<0.001

In individual subgroup analysis, we found that a longer OS was also observed in patients in the low-FAR group in the \< 5 cm and ≥ 5 cm subgroups (*P* \< 0.001 and *P* = 0.001), superficial and deep subgroups (*P* \< 0.001 and *P* = 0.001), stage I/II and III/IV subgroups (*P* \< 0.001 and *P* = 0.014), and G1/G2 subgroup (*P* \< 0.001), but not in the G3 subgroup (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Kaplan-Meier curves showing OS according to the optimal value of FAR in \< 5 cm subgroup (**a**); ≥5 cm subgroup (**b**); Superficial subgroup (**c**); Deep subgroup (**d**); G1--2 subgroup (**e**); G3 subgroup (**f**); I + II subgroup (**g**); and III + IV subgroup (**h**)

Discussion {#Sec12}
==========

To the best of our knowledge, this was the first study to evaluate the prognostic value of the FAR in STS. Our study demonstrated that preoperative FAR is independently associated with survival in resected STS patients.

Accumulating data has indicated that fibrinogen may provide favorable conditions for tumor development and progression in various malignancies \[[@CR10]\]. However, the molecular mechanism underlying this relationship remains unclear. Fibrinogen is a dimeric molecule and serves as a scaffold for binding members of growth factors. This binding could promote tumor cell proliferation and stimulate angiogenesis \[[@CR16]\]. Another possible mechanism may be related to the positive feedback loop between platelets and fibrinogen levels. Fibrinogen could help platelets adhere to cancer cells. In turn, these platelets induce more fibrinogen to aggregate around cancer cells, forming micro emboli in targeted organs \[[@CR17]\]. In addition, these fibrinogen-platelet micro thrombi could functionally enhance tumor migration by preventing circulating tumor cells from natural killer cells or other cytotoxic cells \[[@CR18]\]. A third potential mechanism that may influence prognosis is that fibrinogen may promote the inflammatory response by inducing the overproduction of pro-inflammatory cytokines in malignant cells \[[@CR19]\]. As such, it is believed that these inflammatory responses present in the tumor microenvironment may be one of the factors responsible to provide a favorable medium for facilitating tumor proliferation, invasion, and metastases \[[@CR20]\].

Albumin, as a chronic phase protein, is an indicator represents the nutritional status of the host, as well as a marker of systemic inflammatory response. Several studies have reported that hypoalbuminemia due to poor performance, weight loss and malnutrition is associated with poor prognosis and postoperative complications in patients with different malignancies \[[@CR21]--[@CR23]\], including STS \[[@CR24]\]. These findings can be explained by the fact that hypoalbuminemia may weaken the human defense mechanisms, blunting the therapeutic response and further accelerating the tumor progression. Further, in patients who suffer from simultaneous nutritional decline, they are more likely to have reduced ability to endure aggressive anti-cancer therapeutics \[[@CR25]\].

NLR and PLR are the commonly used blood sample-derived systemic inflammatory response indicators (SIR). Several studies have shown that NLR and PLR were independent prognostic factors in cancer patients \[[@CR26], [@CR27]\]. However, there are also some studies showing that NLR and PLR were ineffective in predicting the prognosis \[[@CR28]--[@CR30]\], indicating the prognostic role of NLR and PLR in cancer still need further investigation. They may should be assessed together with other markers due to the confounding factors regulating by inflammatory conditions.

Considering the above-mentioned evidence, in this study we successfully formulated a new technique by combining both serum fibrinogen and Alb, the FAR, which may have a potent and convincing prognostic ability. Of note, Matsuda et al. \[[@CR31]\] recently established a prognostic indicator based on fibrinogen and Alb levels (FA score) and reported that the FA score system could predict the prognosis of patients with esophageal cancer. However, FA may estimate the coagulation and nutrition level erroneously because it evaluates the values of fibrinogen and Alb separately through categorization. Conversely, the FAR is a continuous variable that is calculated using two continuous variables, which reduces the potential bias and stratifies patients to predict survival more accurately.

According to the ROC curve, our data not only showed that the AUC value of FAR was superior to those of the NLR and PLR but also, the optimal FAR cutoff value to predict OS was at 0.0726. These results demonstrated that comparing other inflammation-based prognostic indices, the FAR had comparable prognostic capability and may be more powerful than NLR and PLR.

More importantly, our results also demonstrated that FAR might indicate a more aggressive tumor behavior and associate with the systemic progression of STS since an elevated FAR was significantly related to larger tumor size, aggressive tumor grade, more advanced AJCC stage and worsen prognoses. These findings were in agreement with previous studies demonstrating that FAR was correlated a longer tumor length, deeper tumor invasion, and increased regional lymph node involvement in ESCC patients \[[@CR32]\].

Moreover, FAR showed a significant association with both DFS and OS in univariate analysis and was identified as an independent prognostic factor for OS in multivariate analysis. Patients with a high FAR had 1.907 times the risk of death of those with a low FAR. These results suggest that FAR has a substantial impact on patient outcome. In addition, PLR, the other index reflecting coagulation and nutrition status was also an independent prognostic factor. However, we failed to show a clear association between FAR and PFS in multivariate analysis. This may be potentially due to the small sample size, which allows a wide variability in terms of results. Another possible limitation is that unrecorded adjuvant treatments may have affected primary tumor progression.

Surprisingly, AJCC stage was not an independent predictor of OS and DFS in our analysis, which is in contrast with a previous large-scale study \[[@CR33]\]. This could be due to the staging defects of human subjectivity and the heterogeneity of STS. The recently released 8th AJCC stage system illustrated an unprecedented change for risk stratification by redefining the T-stage categories \[[@CR34]\]. However, the system still needs further investigation. Our data suggest that the FAR could potentially be an effective biomarker and may complement TNM staging predictions to improve risk stratification.

Further subgroup analysis found that a high FAR was associated with decreased OS in patients across all size, depth and AJCC stage subgroups. However, the FAR was not significantly associated with OS for G3 patients. These results suggest that FAR is more predictive of survival in STS patients with low-grade tumors.

It is worth noting that our findings may have important implications for individualized treatment and surveillance of patients with STS. Patients with an elevated FAR may require additional neoadjuvant therapy or more intense adjuvant chemotherapy to reduce the risk of recurrence. Both fibrinogen and Alb are routinely measured in clinical practice; the FAR has the advantage of being inexpensive, repeatable and standardized, thus offering reduced costs and increased convenience for prognostication.

This study has several limitations. First, our study used a retrospective review involving a single-center with a small sample size, which may lead to selection bias. Second, information on operation approach and adjuvant therapy was incomplete, which could lead to potential biases. Moreover, we lacked of verification analysis, which would further demonstrate our conclusions. Therefore, our results need to be verified in a large-scale prospective cohort.

Conclusions {#Sec13}
===========

In summary, FAR is associated with tumor progression and can be considered an independent factor for OS of resected STS patients. Moreover, compared to the NLR and PLR, the FAR showed comparable prognostic ability based on our study population. Validation studies or large-scale prospective studies are warranted to verify our findings.

Additional file
===============

 {#Sec14}

Additional file 1:**Table S1.** ROC analyses for prognostic indicators. (DOC 32 kb)
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